This proof-of-principle study sought to enhance the therapeutic potential of MSCs in experimental lung injury due to pneumonia by stabilizing the transcription factor HIF-1α with the pharmacological agent AKB-4924. This evidence concerns the gene HIF1A and susceptibility to pneumonia measurement.